Microlocalization and clinical significance of stabilin-1⁺ macrophages in treatment-naïve patients with urothelial carcinoma of the bladder

Bo Wang¹,² · Hao Huang¹ · Meihua Yang¹ · Wenjuan Yang³ · Zhuowei Liu⁴ · Weibin Hou¹ · Hong Zeng⁵ · Zhihua He¹ · Tianxin Lin¹,² · Jian Huang¹,²

Received: 28 September 2018 / Accepted: 12 June 2019 © The Author(s) 2019

Abstract

Purpose Emerging evidence has shown that macrophages (Mφs) at different tumor sites have diverse clinical attributes. Stabilin-1 is a multi-functional scavenger marker for specialized tumor-associated Mφs. This study investigates the relationship between the density and microlocalization of stabilin-1⁺ Mφs within tumors and the clinical outcomes of patients with urothelial carcinoma of the bladder (UCB).

Methods In this retrospective study, 283 UCB patients who received radical cystectomy or transurethral resection were examined. Immunohistochemistry and immunofluorescence analyses were used to colocalize the expression of stabilin-1 with other markers for Mφs (CD14, CD68, CD163, and CD206). Kaplan–Meier analysis and Cox proportional hazards regression models were applied to estimate overall survival (OS) and recurrence-free survival (RFS).

Results In UCB tissues, stabilin-1 was primarily expressed on Mφs, as evident from triple immunofluorescence staining for stabilin-1 and Mφ markers. Stabilin-1⁺ Mφs were often more prominent in stromal regions rather than intratumoral regions in UCB tissues (P < 0.0001). After dichotomization at the median cell density for stabilin-1⁺ Mφs, only intratumoral stabilin-1⁺ Mφ density was a predictor of poor OS (P < 0.001) and RFS (P = 0.026). Moreover, intratumoral stabilin-1⁺ Mφ density was positively associated with tumor stage (P < 0.01) and histological grade (P < 0.01), and emerged as an independent prognostic factor for OS (HR 2.371; P < 0.0001), but not for RFS (HR 1.491; P = 0.061).

Conclusions Our findings indicate that intratumoral stabilin-1⁺ Mφs could potentially be used as a pro-tumoral prognostic marker for UCB patients.

Keywords Urothelial carcinoma of the bladder · Tumor-associated macrophages · Stabilin-1 · Microlocalization

Introduction

Urothelial carcinoma of the bladder (UCB) is the most common type of urological tumor in China [1]. UCB is commonly categorized as non-muscle-invasive bladder cancer...
(NMIBC) and muscle-invasive bladder cancer (MIBC) [2]. Multiple studies have demonstrated that MIBC has a poorer prognostic outcome than NMIBC [3, 4]. With regard to prognosis, lymph node metastasis and grading systems have been incorporated into prognostic models for predicting the progression of UCB [5]. Recent studies have highlighted the importance of the inflammation, which provides important pro-tumoral function and affects the prognosis of bladder patients [6].

Tumors develop in a very complex microenvironment comprising heterogeneous inflammatory cells for the sustained growth, invasion, and metastasis of tumors [7, 8]. Macrophages (Mφs) are a major component of the leukocyte infiltrate in both mouse and human tumors [9, 10]. Different subsets of tumor-associated Mφs (TAMs) are involved in stimulating angiogenesis/lymphangiogenesis, suppressing antitumor immunity and enhancing tumor cell invasion and metastasis [11]. Diverse specific markers are used to distinguish between Mφ subsets in mice [12], a few of which could be used for the differentiation of human Mφ subsets [12, 13]. In humans, CD14 and CD68 are considered as pan markers of Mφ, but they cannot be used to identify the phenotype or functional status of Mφs [13]. Scavenger receptors of CD206 and CD163 have been used to identify certain protumorigenic TAM populations, and it has been shown that a high density of TAMs is associated with an adverse clinical outcome in the case of most solid cancers [13, 14]. However, a recent study showed that cells with a mature TAM phenotype expressed combinations of previously classified pro-tumorigenic (CD163 and CD206) and anti-tumorigenic (CD169 and CD38) markers in renal cell carcinoma [15]. Therefore, a more detailed understanding of TAM phenotypes in the tumor microenvironment would be useful for investigating and therapeutically targeting these cells.

Stabilin-1 is a type 1 transmembrane receptor and a multifunctional scavenger marker of specialized tissue Mφs; it is involved in receptor-mediated endocytosis, intracellular sorting, and tissue remodeling [16]. Evidence has shown that the tumor microenvironment promotes upregulation of the expression of stabilin-1 in Mφs [17]. Kzhyshkowska et al. demonstrated that stabilin-1+ Mφs induced breast tumor growth by mediating silent clearance of extracellular antitumoral factors in mice model [18, 19]. Karikoski et al. found that stabilin-1 could increase immune evasion and lymphatic spread of tumor cells in melanoma and lymphoma [19]. Furthermore, a high density of tumor-infiltrating stabilin-1+ Mφs is associated with adverse patient outcomes in breast cancer and colorectal carcinoma [20, 21]. However, little is known about the microlocalization, density, and clinical relevance of stabilin-1+ Mφs in human bladder cancer.

Herein, we investigated the distribution and prognostic significance of stabilin-1+ Mφs in UCB patients, particularly focused on their anatomic microlocalization. Our data showed that the density of stromal stabilin-1+ Mφs is much higher than that of intratumoral stabilin-1+ Mφs, but that only intratumoral stabilin-1+ Mφ density is a predictor of poor prognosis and is positively associated with tumor stage and histological grade.

**Materials and methods**

**Patients and tissue specimens**

This study included 283 patients with pathologically confirmed UCB at the Cancer Center of Sun Yat-sen University between Jan 2003 and Dec 2009. All patients underwent cystectomy or transurethral resection for UCB; no patients received any immunotherapy or radiotherapy before surgery, as these pretreatments may affect our results. All the samples were anonymously coded in accordance with the local ethical guidelines (as stipulated by the Declaration of Helsinki). Follow-up information was obtained from the Cancer Center Tumor Registry [22]. Overall survival (OS) was defined as the interval between surgery and death or last observation, and recurrence-free survival (RFS) was defined as the interval between surgery and recurrence or last observation.

**Immunohistochemistry and immunofluorescence analyses**

Formalin-fixed and paraffin-embedded samples were processed for immunohistochemical analysis as previously described [23, 24]. After incubation with antibodies against human stabilin-1 (AF3825, R&D system) or control antibody, the sections were incubated with secondary antibodies in an Envision System (Dako).

For triple-color immunofluorescence staining, samples were incubated with sheep anti-human stabilin-1, rabbit anti-human CD14 (10073-R001, Sino Biological) and mouse anti-human CD68 (PG-M1, Dako), or sheep anti-human stabilin-1, rabbit anti-human CD206 (ab64693, Abcam), and mouse anti-human CD163 (ZM-0428, ZSGB-BIO). Images were captured and analyzed on a Zeiss LSM710 system with the ZEN software (Zeiss, Oberkochen, Germany). Single- or double-positive cells of interest in each of two-to-five representative fields at 200× magnification (0.16 mm² per field) were counted manually by two independent blinded observers. Data are expressed as mean ± SEM to indicate the number of cells per field.

**Immunohistological analysis**

The sections were analyzed by two independent observers who were blinded to the clinical outcome. The infiltrating cells in the tissues were categorized according to different
regions: intratumoral (INT) and stromal (ST) regions. To evaluate the density of tissue-infiltrating stabilin-1+ Mφs, tissue sections were screened under a low-power field (100×), and the five most representative fields were selected for analysis at 400× magnification (0.07 mm² per field). The number of infiltrating cells per field was expressed as the mean ± SEM. The average counts reported by the two investigators were used in subsequent analyses to minimize inter-observer variability.

**Statistical analyses**

Statistical analyses were performed using Stata 13.0 (Stata Corp, College Station, TX, USA). The statistical significance of differences between groups was determined using the Wilcoxon signed-rank test. Cumulative survival was calculated using the Kaplan–Meier method and was analyzed by the log-rank test. A multivariate Cox proportional hazards model was used to estimate the adjusted hazard ratios and 95% confidence intervals (CIs), and to identify independent prognostic factors. For categorical analyses, the median value was used as a cutoff to dichotomize continuous variables (for clinical applications). Associations between variables were analyzed using Spearman ρ coefficient tests, and relationships between categorical variables were analyzed using χ² tests. For such comparisons, two-tailed P values that were < 0.05 were considered to indicate statistical significance.

**Results**

**Subpopulation of TAMs in human UCB tissues based on stabilin-1 expression**

We used immunostaining to examine whether TAMs express stabilin-1 and their distribution patterns in human UCB tissues. Stabilin-1 was primarily expressed on Mφs, which was demonstrated by co-expression of stabilin-1 and other markers of Mφs (CD14, CD68, CD163, and CD206) in triple-color immunofluorescence stains (Fig. 1a–c). Stabilin-1 was also expressed on some endothelium cells and/or lymphatic vessels in several UCB tissues, but these cells are easily excluded based on morphology (Supplementary Fig. 1; Fig. 1d). Moreover, we found that stabilin-1+ Mφs were distributed throughout the tissues and that they were more frequent in stromal regions than in the corresponding intratumoral regions (20 ± 17 and 4 ± 8 cells/field, respectively; Fig. 1d, e).

**Association between stabilin-1+ Mφ density and survival in treatment-naïve UCB patients**

To investigate the prognostic role of stabilin-1+ Mφs in UCB, 283 treatment-naïve UCB patients who had long-term follow-up data (> 10 years) were divided into two groups according to the median counts of stabilin-1+ Mφs in the intratumoral regions (stabilin-1+ INT Mφs) and stromal regions (stabilin-1+ ST Mφs), respectively. Kaplan–Meier analysis revealed a negative association between the density of stabilin-1+ INT Mφs and both OS (P < 0.001, Fig. 2a) and RFS (P = 0.025, Fig. 2b). Patients with a high density of stabilin-1+ INT Mφs had significantly shorter OS (median, 72 months) and RFS (median, 53 months) than patients with a low density of stabilin-1+ INT Mφs (median OS, 84 months; median RFS, 72 months). However, the stabilin-1+ ST Mφ density did not correlate with the survival of UCB patients (Fig. 2c, d). According to the results of univariate analysis, stabilin-1+ INT Mφ density was associated with both OS and RFS (Table 1). When the clinicopathologic features that were significant in univariate analysis were adopted as covariates (Table 1), multivariate analysis revealed that stabilin-1+ INT Mφs was an independent prognostic factor for OS (HR 2.371; P < 0.0001), but not for RFS (HR 1.491; P = 0.061).

We also evaluated the influence of stabilin-1+ INT Mφs in combination with age, tumor stage, and nodal status using the Wald test for interaction (Pinteraction). In the multivariate model, combinations of stabilin-1+ INT Mφ with age (HR 2.095; Pinteraction = 0.001), tumor stage (HR 2.001; Pinteraction = 0.003), and nodal status (HR 1.614; Pinteraction < 0.001) emerged as powerful independent predictors of shorter OS (Table 2).

**Association of stabilin-1+ Mφ density in distinct microlocations with tumor progression**

Among the 283 treatment-naïve UCB patients, 86 patients (31.4%) had MIBC and 117 patients (41.3%) had high histological grade tumors (Supplementary Table 1). The density of stabilin-1+ INT Mφs, but not stabilin-1+ ST Mφs, was positively associated with tumor stage (P = 0.005) and histological grade (P = 0.005, Supplementary Table 2). Lymph node metastasis (N1–N2) was confirmed in 16 out of the 283 UCB treatment-naïve patients (5.7%). The density of neither stabilin-1+ INT Mφs nor stabilin-1+ ST Mφs was significantly associated with lymphatic metastasis.

**Discussion**

In the present study, we found that stabilin-1 and other markers for Mφs (CD14, CD68, CD163, and CD206) could be partly co-expressed on the same Mφs, and that stabilin-1+ Mφs were distributed more prominently in the ST than in...
the INT regions in UCB tissues. However, a high density of stabilin-1$^{+}$ INT Mφs, but not stabilin-1$^{+}$ ST Mφs, was found to be a predictor of poor prognosis in UCB patients, and was positively associated with tumor stage and pathologic grade. These data provide new insights into the significance of the microlocalization, density, and functional orientation of stabilin-1$^{+}$ Mφs in UCB tumor progression.

Human tumor tissues can be anatomically classified into intratumoral and stromal regions, and each has distinct compositional and functional properties [25, 26]. TAMs have various functions according to their microlocalization [25, 27]. Therefore, we focused on the tissue microlocalization of stabilin-1$^{+}$ Mφs in UCB tissues. Our data showed that the density of INT-infiltrating stabilin-1$^{+}$ Mφs emerged as an independent predictor of prognosis. In accordance with our results, the previous studies have also shown that a high density of tumor-infiltrating stabilin-1$^{+}$ Mφs is associated with worse prognosis in colorectal and breast cancers [21, 28]. However, Boström et al. suggested that the stabilin-1$^{+}$ Mφ density is not associated with survival in a group of 184 UBC patients [29]. The contrasting results are probably a result of differences in the tumor stage, number, and size of tumors, as death and recurrence have vastly different probabilities depending on tumor stage. Another important difference is that the Boström study did not evaluate the distribution of Mφs in different microlocations of UCB.

Fig. 1 Expression of stabilin-1 and its distribution pattern in human UCB tissues. Paraffin-embedded UCB sections (n ≥ 10) were subjected to triple-color immunofluorescence staining for stabilin-1 (red) and either a the pan-Mφ marker CD14 (green) and CD68 (white) or b the alternative Mφ marker CD206 (green) and CD163 (white), with DAPI counterstaining (blue). The high-power fields show the colocalization of stabilin-1 with the indicated markers (white arrows). Scale bar, 20 µm. c Proportion of other Mφs/stabilin-1$^{+}$ Mφs in UCB sections (n > 10). Data are expressed as mean ± SEM (bars). d, e Stabilin-1$^{+}$ Mφs are enriched in the stromal regions of UCB tissues (n = 287). d Representative immunohistochemistry images of stabilin-1$^{+}$ Mφs in human UCB tissues (black arrows). Stabilin-1 is also expressed on some endothelium cells (red arrows). The micrographs at higher magnification show stained intratumoral regions (INT) and stromal regions (ST). Scale bar, 100 µm. e Number of stabilin-1$^{+}$ Mφs in the INT and ST regions of human UCB tissues. Cell numbers were calculated as the cell count per ×400 field. Data are expressed as mean ± SEM values.
Fig. 2 Accumulation of stabilin-1+ Mφs in intratumoral regions as a predictor of adverse prognosis in UCB patients (n=283). Patients were divided into two groups according to the median number of cells per ×400 field. a, c Stabilin-1+ Mφs in intratumoral regions (stabilin-1+ INT Mφs, median = 0). b, d Stabilin-1+ Mφs in stromal regions (stabilin-1+ ST Mφs, median = 16). The cumulative overall survival time and recurrence-free survival time were calculated using the Kaplan–Meier method and analyzed with the log-rank tests. Black lines, low density of stabilin-1+ Mφs; red lines, high density of stabilin-1+ Mφs.

Table 1 Univariate and multivariate analyses of factors associated with mortality and recurrence in urothelial carcinoma of the bladder (n=283)

| Variable | Overall survival | Recurrence |
|----------|-----------------|------------|
|          | Univariate | Multivariate | Univariate | Multivariate |
|          | HR | 95% CI | P value | HR | 95% CI | P value |
| Age, year (> 60 vs. ≤ 60) | 4.6×10⁻⁶ | 3.47 | 2.107–5.713 | <0.0001 | 0.187 | NA |
| Gender (female vs. male) | 0.19 | NA | NA | 0.972 | NA | NA |
| Tumor size (> 3 vs. ≤ 3 cm) | 0.016 | 1.286 | 0.755–2.192 | 0.354 | 0.721 | NA |
| Multifocality (multifocal vs. unifocal) | 0.947 | NA | NA | 0.34 | NA | NA |
| Tumor stage (T2–T4 vs. Ta–T1) | 8.5×10⁻⁷ | 2.292 | 1.308–4.016 | 0.004 | 0.964 | NA |
| Nodal status (N1–N2 vs. N0) | 4×10⁻⁶ | 2.541 | 1.214–5.315 | 0.013 | 0.151 | NA |
| Histological grade (G3 vs. G1–G2) | 3.7×10⁻⁴ | 2.541 | 0.691–2.026 | 0.54 | 0.007 | 1.661 | 1.099–2.509 | 0.016 |
| Stabilin-1⁺ INT Mφ density (high vs. low) | 1.8×10⁻⁴ | 2.371 | 1.477–3.803 | <0.0001 | 0.026 | 1.491 | 0.981–2.265 | 0.061 |
| Stabilin-1⁺ ST Mφ density (high vs. low) | 0.605 | 0.763 | NA | NA | NA | NA |

Univariate and multivariate analyses. Cox proportional hazards regression model. Variables associated with survival by univariate analysis were adopted as covariates in multivariate analyses. Significant P values are shown in bold.

UCB urothelial carcinoma of the bladder, Stabilin-1⁺ INT Mφs stabilin-1⁺ Mφs in intratumoral regions, Stabilin-1⁺ ST Mφs stabilin-1⁺ Mφs in stromal regions, HR hazard ratio, CI confidence interval, NA not applicable.

HR > 1, higher risk of death; HR < 1, lower risk of death.

 Springer
tissues. However, in our study, only high density of INT-infiltrating stabilin-1+ Mφs could predict poor survival in UCB patients. Furthermore, our previous study showed that the density of ST-infiltrating CD204+ Mφs, but not INT-infiltrating CD204+ Mφs, was a sign of poor prognosis in treatment-naïve UCB patients [23]. Gao et al. have demonstrated PD-L1 and VISTA expression on predominantly treatment-naïve UCB patients. Furthermore, our previous study showed that stabilin-1+ Mφs in INT regions were positively associated with tumor stage and histological grade. However, this parameter was not associated with lymph node metastasis; this is probably a result of the low number of lymph node metastasis events and lower statistical power of the findings.

### Conclusion

Our findings indicate that stabilin-1, which is considered a potent pro-tumoral Mφ phenotype marker. The density of stabilin-1+ Mφs was positively correlated with disease progression and stabilin-1 could potentially be used as a prognostic marker for UCB patients.

### Acknowledgements

This study was supported by the National Natural Science Foundation of China (Grant nos. 81402106, 81825016); the Science and Technology Program of Guangzhou (Grant nos. 201604020177, 201604020156); the National Natural Science Foundation of Guangdong (Grant no. 2015A030310122); the Pearl River Nova Program of Guangzhou (Grant no. 201806010024); the Cultivation of Major Projects and Emerging, Interdisciplinary Fund, Sun Yat-Sen University (Grant no. 16ykjc18); Elite Young Scholars Development Program of Sun Yat-Sen Memorial Hospital to Bo Wang; Yat-Sen Scholarship for Young Scientist to Bo Wang; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University (Grant no. KLB09001);

### Table 2

| Combined variable | Univariate | Multivariate |
|-------------------|------------|--------------|
|                    |            | P           | HR | 95% CI | P  |
| Stabilin-1<sub>INT</sub> Mφs and age |            | <0.001     | 1.77 | 1.425–2.199 | <0.001 |
| Low stabilin-1<sub>INT</sub> Mφ density, age ≤ 60 |            |            | 1  |
| Low stabilin-1<sub>INT</sub> Mφ density, age > 60 |            |            | 3.53 | 1.693–7.355 | 0.001 |
| High stabilin-1<sub>INT</sub> Mφ density, age ≤ 60 |            |            | 2.3  | 1.011–5.239 | 0.047 |
| High stabilin-1<sub>INT</sub> Mφ density, age > 60 |            |            | 8.38 | 3.974–17.651 | <0.001 |
| Stabilin-1<sub>INT</sub> Mφs and T stage |            | <0.001     | 1.7  | 1.387–2.092 | <0.001 |
| Low stabilin-1<sub>INT</sub> Mφ density, Ta–T1 |            |            | 1  |
| Low stabilin-1<sub>INT</sub> Mφ density, T2–T4 |            |            | 2.22 | 1.133–4.358 | 0.02  |
| High stabilin-1<sub>INT</sub> Mφ density, Ta–T1 |            |            | 1.98 | 1.030–3.795 | 0.04  |
| High stabilin-1<sub>INT</sub> Mφ density, T2–T4 |            |            | 6.23 | 3.318–11.689 | <0.001 |
| Stabilin-1<sub>INT</sub> Mφs and nodal status |            | <0.001     | 1.61 | 1.294–2.013 | <0.001 |
| Low stabilin-1<sub>INT</sub> Mφ density, N0 |            |            | 1  |
| Low stabilin-1<sub>INT</sub> Mφ density, N1–N2 |            |            | 4.02 | 1.493–10.832 | 0.006 |
| High stabilin-1<sub>INT</sub> Mφ density, N0 |            |            | 2.56 | 1.566–4.187 | <0.001 |
| High stabilin-1<sub>INT</sub> Mφ density, N1–N2 |            |            | 5.28 | 1.933–14.431 | 0.001 |

Univariate and multivariate analyses. Cox proportional hazards regression model. Variables associated with survival by univariate analysis were adopted as covariates in multivariate analyses. Significant P values are shown in bold

UCB urothelial carcinoma of the bladder, Stabilin-1<sub>INT</sub> Mφs stabilin-1+ Mφs in intratumoral regions, HR hazard ratio, CI confidence interval, NA not applicable

HR > 1, higher risk of death; HR < 1, lower risk of death
and Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology (Grant no. 013-163).

**Author contributions** BW: protocol/project development, data analysis, and manuscript writing/editing; HH: protocol/project development, data collection or management, and manuscript writing/editing; MY: data collection or management; WY: data collection or management; ZL: data collection or management; WH: data collection or management; HZ: data analysis; TL: protocol/project development and manuscript writing/editing; JH: protocol/project development and manuscript writing/editing.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the license, and indicate if changes were made.

**References**

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu QX, He J (2016) Cancer statistics in China. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.212338
2. Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat EM, Hernandez V, Kaasinen E, Palou J, Roupret M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.euro.2016.05.041
3. Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, Huang H, Yao Y, Guo Z, Xie W (2016) Laparoscopic radical cystectomy with orthotopic ileal neobladder for bladder cancer: oncologic results of 171 cases with a median 3-year follow-up. Eur Urol 58(3):442–449. https://doi.org/10.1016/j.euro.2010.05.046
4. Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, Neuzillet Y, Veskimae E, van der Heijden AG, Gakis G, Ribal MJ (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.euro.2016.06.020
5. Ku JH, Kang M, Kim HS, Jeong CW, Kwak C, Kim HH (2015) Lymph node density as a prognostic variable in node-positive bladder cancer: update 2016. Eur Urol 71(3):447–461. https://doi.org/10.1016/j.euro.2016.06.020
6. Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, Gschwend JE, Kubiher HR, Slotta-Huspenina J (2016) The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol 34(2):181–187. https://doi.org/10.1007/s00345-015-1615-3
7. Taniguchi K, Karin M (2018) NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18(5):309–324. https://doi.org/10.1038/nri.2017.142
8. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564. https://doi.org/10.1126/science.1203543
9. Okabe Y, Medzhhitov R (2016) Tissue biology perspective on macrophages. Nat Immunol 17(1):9–17. https://doi.org/10.1038/ni.3320
10. Epelman S, Lavine KJ, Randolph GJ (2014) Origin and functions of tissue macrophages. Immunity 41(1):21–35. https://doi.org/10.1016/j.immuni.2014.06.013
11. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399–416. https://doi.org/10.1038/nrclinonc.2016.217
12. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141(1):39–51. https://doi.org/10.1016/j.cell.2010.03.014
13. Guerrero JL (2018) Macrophages: the road less traveled, changing anticancer therapy. Trends Mol Med 24(5):472–489. https://doi.org/10.1016/j.molmed.2018.03.006
14. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4(1):71–78. https://doi.org/10.1038/nrc1256
15. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moh C, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe’er D, Bodenmiller B (2017) An immune atlas of clear cell renal cell carcinoma. Cell 169(4):736–749 e718. https://doi.org/10.1016/j.cell.2017.04.016
16. Kuzhshkowska J, Mamiidi S, Gratchev A, Kremmer E, Schmuttermayer C, Krussel L, Haus G, Uitkal J, Schledzewski K, Scholte J, Goerdt S (2006) Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 107(8):3221–3228. https://doi.org/10.1182/blood-2005-07-2843
17. David C, Nance JP, Hubbard J, Hsu M, Binder D, Wilson EH (2012) Stabilin-1 expression in tumor associated macrophages. Brain Res 1481:71–78. https://doi.org/10.1016/j.brainres.2012.08.048
18. Riabov V, Yin S, Song B, Avdiev A, Schledzewski K, Ovsisy I, Gratchev A, Llopos Verdiell M, Sticht C, Schmuttermayer C, Schonheimer H, Weiss C, Fields AP, Simon-Keller K, Pfitser F, Berlit S, Marx A, Arnold B, Goerdst S, Kuzhshkowska J (2016) Stabilin-1 is expressed in human breast cancer and supports tumor growth in mammary adenocarcinoma mouse model. Oncotarget 7(21):31097–31110. https://doi.org/10.18632/oncotarget.8857
19. Karikoski M, Marttila-Ichihara E, Eilma K, Rantakari P, Hollmen M, Kelkka T, Gerke H, Huovinen V, Irjala H, Holmdahl R, Salmi M, Jalkanen S (2014) Clever-1/stabilin-1 controls cancer growth and metastasis. Clin Cancer Res 20(24):6452–6464. https://doi.org/10.1158/1078-0432.CCR-14-1236
20. Palani S, Maksimov M, Miiluniemi M, Auviken K, Jalkanen S, Salmi M (2011) Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages. Eur J Immunol 41(7):2052–2063. https://doi.org/10.1002/eji.201041376
21. Buldakov M, Zavalova M, Krakhmal N, Telezina N, Tvorushin S, Mitrofanova I, Riabov V, Yin S, Song B, Cherdynseva N, Kuzhshkowska J (2017) CD68*, but not stabilin-1* tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiology 222(1):31–38. https://doi.org/10.1016/j.imbio.2015.09.011
22. Wang B, Wu S, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J (2015) CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol 194(2):556–562. https://doi.org/10.1016/j.juro.2015.02.2941

23. Wang B, Liu H, Dong X, Wu S, Zeng H, Liu Z, Wan D, Dong W, He W, Chen X, Zheng L, Huang J, Lin T (2015) High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget 6(24):20204–20214. https://doi.org/10.18632/oncotarget.3887

24. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij JP, Schultz LE, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41(1):14–20. https://doi.org/10.1016/j.immuni.2014.06.008

25. Wu Y, Zheng L (2012) Dynamic education of macrophages in different areas of human tumors. Cancer Microenviron 5(3):195–201. https://doi.org/10.1007/s12307-012-0113-z

26. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306. https://doi.org/10.1038/nrc3245

27. Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33(3):119–126. https://doi.org/10.1016/j.it.2011.12.001

28. Algars A, Irjala H, Vahtinen S, Huhtinen H, Sundstrom J, Salmi M, Ristamaki R, Jalkanen S (2012) Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer 131(4):864–873. https://doi.org/10.1002/ijc.26457

29. Bostrom MM, Irjala H, Mirtti T, Taimen P, Kauko T, Algars A, Jalkanen S, Bostrom PJ (2015) Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer. PLoS One 10(7):e0133552. https://doi.org/10.1371/journal.pone.0133552

30. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstratiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blaž J, Sharma P (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551–555. https://doi.org/10.1038/nm.4308

31. Rantakari P, Patten DA, Valtonen J, Karikoski M, Gerke H, Dawes H, Laurila J, Ohlmeier S, Elima K, Hubsher SG, Weston CJ, Jalkanen S, Adams DH, Salimi M, Shetty S (2016) Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury. Proc Natl Acad Sci USA 113(33):9298–9303. https://doi.org/10.1073/pnas.1604780113

32. Irjala H, Alaken K, Grenman R, Heikila P, Joensuu H, Jalkanen S (2003) Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res 63(15):4671–4676

33. Palani S, Elima K, Ekholm E, Jalkanen S, Salmi M (2016) Monocyte stabilin-1 suppresses the activation of TH1 lymphocytes. J Immunol 196(1):115–123. https://doi.org/10.4049/jimmunol.1500257

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.